BioSpace News Archive

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced it has been added to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes effective after the U.S. markets open , June 28, 2021, as part of the 2021 Russell US Indexes Reconstitution.

Clovis Oncology, Inc., announced that Professor Dr. Richard P. Baum and Dr. Harshad R. Kulkarni, in conjunction with 3B Pharmaceuticals, published a retrospective report of their independent experience with FAP-2286 in named-patient use in The Journal of Nuclear Medicine.

Ribometrix, a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases, announced the appointment of Manjunath Ramarao, Ph.D., as senior vice president in its research and development team.

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, announced the appointment of Paul Brannelly as Chief Financial Officer.

Crinetics Pharmaceuticals, Inc. today announced the randomization of the first acromegaly patient in its Phase 3 clinical trial of paltusotine, PATHFNDR-1 Study.

Pinteon Therapeutics today announced positive results from its Phase 1 study of PNT001.

9 Meters Biopharma, Inc. announced today it has joined the broad-market Russell 3000 Index and the small-cap Russell 2000 Index at the conclusion of the Russell U.S. Indexes annual reconstitution.

There has been augmented focus on personalized medicines and drug discovery utilizing in vitro methods.

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that the U.S. Food and Drug Administration has cleared the company’s Investigational New Drug Application for ORIC-533 to proceed into a first-in-human clinical trial.

Cocrystal Pharma, Inc., a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, announces that it will be added to the Russell Microcap® Index after the U.S. market opens , June 28, 2021.